<DOC>
	<DOCNO>NCT01633476</DOCNO>
	<brief_summary>The purpose study determine whether Cytomegalovirus ( CMV ) reactivation ANCA-associated vasculitis ( AAV ) patient effectively safely reduce use antiviral agent ( valaciclovir ) whether turn improve function immune system thereby also improve body 's ability fight infection . The primary hypothesis repeat episode CMV reactivation AAV patient drive expansion functional impairment CMV-specific T-cells , increase susceptibility infection . Inhibition CMV replication valaciclovir block stimulation CMV specific T-cells increase functional capacity immune system .</brief_summary>
	<brief_title>CMV Modulation Immune System ANCA-associated Vasculitis</brief_title>
	<detailed_description>Infection common cause death patient ANCA-associated vasculitis ( AAV ) . The investigator show expansion CD4+CD28- T-cells present patient AAV driven CMV expansion associate increased infection risk . It suggest cell drive CMV reactivation express marker T-cell exhaustion reduce cytokine production inhibitory receptor expression . However phenotype CMV-specific T cell extreme expansion CD4+CD28- T-cells explored . The investigator aim investigate phenotype CMV-specific T-cells compare patient extreme expansion CD4+CD28- T-cells small expansion relate CMV reactivation . The investigator monitor CMV reactivation urine blood monthly qPCR . This correlated expansion CD4+CD28- T-cells phenotype cell , specifically look cytokine production inhibitory receptor expression . The investigator identify CMV-specific T-cells MHC class II tetramers stimulate CMV lysate . The investigator proceed undertake randomise controlled trial valaciclovir treatment investigate whether reduction CMV reactivation improve phenotype CD4+CD28- T-cells patient .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Documented diagnosis Wegener 's granulomatosis ( call Granulomatosis Polyangiitis ) , microscopic polyangiitis renal limited vasculitis accord Chapel Hill Consensus Conference criterion . In stable remission ( documented clinical disease activity ) least 6 month prior entry . On maintenance immunosuppression prednisolone , mycophenolate mofetil azathioprine alone combination ( maximum 2 agent ) . Documented evidence CMV infection ( CMVspecific immunoglobulin G detect peripheral blood ) . Documentation female patient child bear potential pregnant use appropriate form contraception . Written inform consent study participation Stage 5 chronic kidney disease ( eGFR &lt; 15ml/minute/1.73m2 ) . Other significant chronic infection ( HIV , HBV , HCV , TB ) . Bcell Tcell deplete therapy within 12 month . Treatment antiCMV therapy last month Underlying medical condition , opinion Investigator place patient unacceptably high risk participate study . Inability fully appropriately participate study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CMV</keyword>
	<keyword>ANCA associate vasculitis</keyword>
	<keyword>CD4+CD28- T-cells</keyword>
	<keyword>Valaciclovir</keyword>
</DOC>